For patients with terminal cancer, chemotherapy does not improve quality of life
the ONA take:
Chemotherapy administered to patients with cancer who are near death does not improve quality of life and may even reduce quality of life in those who have good performance status, a recent study published in JAMA Oncology has shown.
For the study, researchers evaluated 312 patients with terminal cancer who were estimated to live no more than 6 months. The majority were receiving chemotherapy. Results showed that patients with a poor performance status who received chemotherapy achieved no improvement in quality of life during their final week prior to death.
Moreover, researchers found that in those with a good performance status, treatment worsened their quality of life compared with patients with a good performance status who were not receiving treatment.
Current American Society of Clinical Oncology (ASCO) guidelines contend that patients with terminal cancer and a good performance status are the most likely to benefit from chemotherapy, but these findings suggest that chemotherapy given to patients at the end of life may be wasteful, unnecessary, and potentially harmful.
Chemotherapy administered to patients with cancer who are near death does not improve quality of life.
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- Vitamin D Supplementation is Recommended for Pediatric Patients With Sarcoma
- Extended Adjuvant Therapy for Breast Cancer Improves 5-Year Disease-free Survival
- A Structured Group Exercise Program for Patients With Metastatic Cancer Receiving Chemotherapy and CTNNB1 (β-catenin) as a Biomarker of Exercise Efficacy
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|